Cargando…

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage

OBJECTIVES: The significance of antibodies directed against activated factor X (FXa) and thrombin (Thr) in patients with SLE and/or antiphospholipid syndrome (APS) is unknown. FXa and Thr are coregulated by antithrombin (AT) and activate complement. Therefore, we studied the ability of anti activate...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonnell, Thomas, Amarnani, Raj, Spicer, Carina, Jbari, Hajar, Pericleous, Charis, Spiteri, Valentina A, Wincup, Chris, Artim-Esen, Bahar, Mackie, Ian, Botto, Marina, Rahman, Anisur, Giles, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422842/ https://www.ncbi.nlm.nih.gov/pubmed/36007979 http://dx.doi.org/10.1136/lupus-2022-000738

Ejemplares similares

Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I
por: McDonnell, Thomas, et al.
Publicado: (2018)

Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays
por: Artim-Esen, Bahar, et al.
Publicado: (2015)

Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome
por: Artim-Esen, Bahar, et al.
Publicado: (2017)

Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation
por: Albay, A, et al.
Publicado: (2019)

The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS
por: McDonnell, Thomas, et al.
Publicado: (2020)

Comparison of Acquired Activated Protein C Resistance, Using the CAT and ST-Genesia(®) Analysers and Three Thrombin Generation Methods, in APS and SLE Patients
por: Efthymiou, Maria, et al.
Publicado: (2021)

Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome
por: McDonnell, Thomas C R, et al.
Publicado: (2018)

Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS
por: McDonnell, Thomas, et al.
Publicado: (2015)

Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?
por: Pericleous, Charis, et al.
Publicado: (2020)

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes
por: Gill, Dipender, et al.
Publicado: (2020)

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK
por: Bourke, Lauren T, et al.
Publicado: (2017)

PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome
por: Willis, Rohan, et al.
Publicado: (2022)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome
por: Cousins, Laura, et al.
Publicado: (2015)

Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events
por: Farina, Nicola, et al.
Publicado: (2022)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis
por: Lambrianides, Anastasia, et al.
Publicado: (2011)

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
por: Wang, Wenzhi, et al.
Publicado: (2016)

Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches
por: Lagos, Carlos F., et al.
Publicado: (2017)

Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets
por: Han, Wenwen, et al.
Publicado: (2023)

Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome
por: Ripoll, Vera M., et al.
Publicado: (2018)

Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort
por: Segura, Beatriz Tejera, et al.
Publicado: (2019)

Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort
por: Segura, Beatriz Tejera, et al.
Publicado: (2019)

Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus
por: Amarnani, Raj, et al.
Publicado: (2021)

Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study
por: Croca, Sara, et al.
Publicado: (2014)

Purified IgG from Patients with Obstetric but not IgG from Non-obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion
por: Poulton, Katie, et al.
Publicado: (2015)

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity
por: Narita, Yuki, et al.
Publicado: (2019)

Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
por: Gackowski, Marcin, et al.
Publicado: (2023)

Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome
por: Pericleous, Charis, et al.
Publicado: (2016)

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020)

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies
por: Mariño-Ocampo, Nory, et al.
Publicado: (2023)

Oxidation of β2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

The Extended Cleavage Specificity of Human Thrombin
por: Gallwitz, Maike, et al.
Publicado: (2012)

Cell-Free DNA Promotes Thrombin Autolysis and Generation of Thrombin-Derived C-Terminal Fragments
por: Saravanan, Rathi, et al.
Publicado: (2021)

Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus
por: Wincup, Chris, et al.
Publicado: (2021)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
por: Amiral, Jean, et al.
Publicado: (2021)

A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis
por: Torun, Ege Sinan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_36fods9e8t0ku8qapgjnpojn8u